Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

235.90 +6.06 (+2.63%)
Streaming Delayed Price Updated: 2:07 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Madrigal Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades. 
Via InvestorPlace
2 Under-the-Radar Growth Stocks to Consider
Don't ignore these innovative companies. 
Via The Motley Fool
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
These businesses should see good times ahead. 
Via The Motley Fool
1 No-Brainer Growth Stock to Buy Now
This liver-disease specialist might be significantly undervalued. 
Via The Motley Fool
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
This biotech just got clearance to dive into a deep ocean of a market. 
Via The Motley Fool
Madrigal Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
The 3 Best Biotech Stocks to Buy in April 2024
Biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. 
Via InvestorPlace
2 Top Biotech Buyout Candidates
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be... 
Via Talk Markets
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
Both stocks are pretty risky, but one of them more so than the other. 
Via The Motley Fool
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off? 
Via The Motley Fool
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
The mid-cap biotech has succeeded where many others failed. 
Via The Motley Fool
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Madrigal has one key advantage over its two huge potential future rivals. 
Via The Motley Fool
Exposures Product Safety
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring
FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease.... 
Via Benzinga
Exposures Product Safety
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
Via Benzinga
Why Is Geron (GERN) Stock Up 94% Today?
Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing. 
Via InvestorPlace
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported... 
Via Benzinga
Topics Stocks
Exposures US Equities
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today
Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today. 
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH
The company hopes to be the first to the finish line with a treatment for MASH. 
Via Investor's Business Daily
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be in store for all three of these drugmakers. 
Via The Motley Fool
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
This business could be on the cusp of making medical history. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.